Literature DB >> 16481077

Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice.

Maite Estevan1, Carlos Gamazo, María Jesús Grilló, Guillermo García Del Barrio, Jose M Blasco, Juan M Irache.   

Abstract

The aim of this study was to evaluate the effect of the excipients used to facilitate the encapsulation of high hydrophobic antigenic complex extracted from Brucella ovis (HS) on the physico-chemical properties of the resulting microparticles. Poly(epsilon-caprolactone) (PEC) microparticles containing HS were prepared by the solvent extraction/evaporation method using total recirculation one-machine system (TROMS). Different excipients, beta-cyclodextrin (beta-CD), Pluronic F68, Tween 20 or Tween 80, were used in order to facilitate the encapsulation and conserve the bioactivity of the encapsulated antigenic complex. HS was efficiently loaded in all the different PEC-microparticle formulations, although the combined use of beta-cyclodextrin and Pluronic F68 permitted an increase in the amount of antigenic extract in the core of the resulting microparticles without loss of its antigenic properties. Finally, the protective ability of this F68-CD-MP formulation was evaluated against an experimental challenge with the virulent Brucella melitensis H38 strain in BALB/c mice. This innocuous subcellular vaccine induced a similar protection to that of the live attenuated Rev 1 vaccine; these are promising results that would merit further investigation in target animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481077     DOI: 10.1016/j.vaccine.2006.01.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

Review 2.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 3.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

4.  Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development.

Authors:  Samantha Sayers; Guerlain Ulysse; Zuoshuang Xiang; Yongqun He
Journal:  J Biomed Biotechnol       Date:  2012-03-13

5.  Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Authors:  Nicola J Commander; James M Brewer; Brendan W Wren; Stephen A Spencer; Alastair P Macmillan; Judith A Stack
Journal:  Genet Vaccines Ther       Date:  2010-07-16

6.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

Review 7.  Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.

Authors:  Gabriel Gomez; Leslie G Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  Front Cell Infect Microbiol       Date:  2013-05-16       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.